Table 3.
Comparison of efficacy between intravenous regimes that incorporate MTX and vinca alkaloids for DF, that is recurrent/ progressive/ advanced/ or not amenable to surgery/radiation, by treatment duration
| Study | Number (n) | Age(yr) | Treatment | Duration of treatment (median) | Prior treatment number (%) | Overall response rate (%)(CR + PR) | Clinical benefit (%)(CR + PR+SD) | |||
|---|---|---|---|---|---|---|---|---|---|---|
| S | R | M | C | |||||||
| Garbay et al11 | 62 | 30 |
Variable regimens MTX/VBL 27 (43.5) |
18 wk | 33 (53) | 8(13) | 37(54.7) | — | 21(MTX/VBL‐ 15) | 80.6 |
| Skapek et al12 | 26 | 10 | MTX/VBL | 40 wk | — | — | —— | — | 19.2 | 69.2 |
| Li et al13 | 71 | 14 | MTX/VNL | 12 mo | — | — | —— | — | 35.2 | 87.3 |
| Azzarelli et al14 | 30 | 27 | MTX/VBL | 12 mo | 24 (80) | 5(17) | 4(13) | 3(10) | 40 | 100 |
| Palassini et al8 | 75 | 36.6 | Variable Regimens MTX/VNL43 (57.3) | 14 mo | 54(72) | 8(10) | 36(48) | — | 48 (MTX/VNL‐ 51.2) | 98.7 |
| Park et al1 | 22 | 32 | MTX/VBL | 12 mo | 14(64) | — | 4(18) | 2(9) | 52 | 95 |
| Ingley et al | 48 | 33 | MTX/VNL | 19 mo | 9(19) | 1(2) | 23(48) | 1(2) | 81 | 98 |
Abbreviations: n = Number of patients evaluated for response. Age‐ median age of diagnosis/ onset, in years.
Treatment: MTX, methotrexate; VNL, vinorelbine; VBL, vinblastine; n(%) of patients reported who were administered MTX/ vinca alkaloid.
Duration of treatment: when median duration of treatment was not provided, anticipated treatment course was documented; wk, weeks; mo, months.
Prior treatment: S, surgery; R, radiation; M, at least one or more medical treatments‐ NSAIDs, antiestrogens, tyrosine kinase inhibitors; C, chemotherapy.